CNBC
By Ian Thomas
July 2, 2021
Following a breakthrough trial where gene-editing technology CRISPR completed its first systematic delivery as medicine to a human body, Intellia Therapeutics CEO John Leonard said he hopes the gene therapy could be made available to patients “very, very soon.”
“These approaches are subjected to the standard sorts of clinical trials that any drug or gene therapy would be studied under, so we’re in the earlier stages of that,” Leonard said on CNBC’s “Closing Bell” on Thursday afternoon.